Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph T Hull

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Sleep|February 6, 2019
Chronic sleep restriction greatly magnifies performance decrements immediately after awakeningAndrew W McHill, Joseph T Hull, Daniel A Cohen, et al.
Brain and Behavior|February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorderStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Sleep|April 2, 2017
Modeling Neurocognitive Decline and Recovery During Repeated Cycles of Extended Sleep and Chronic Sleep DeficiencyMelissa A St Hilaire, Melanie Rüger, Federico Fratelli, et al.
Psychiatry Research|January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trialsStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Neuropsychiatric Disease and Treatment|June 11, 2021
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled TrialsAzmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
British Journal of Clinical Pharmacology|May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Psychiatry Research|November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trialStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Clinical Therapeutics|March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled TrialAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Sleep|February 6, 2019
Chronic sleep restriction greatly magnifies performance decrements immediately after awakeningAndrew W McHill, Joseph T Hull, Daniel A Cohen, et al.
Brain and Behavior|February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorderStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Sleep|April 2, 2017
Modeling Neurocognitive Decline and Recovery During Repeated Cycles of Extended Sleep and Chronic Sleep DeficiencyMelissa A St Hilaire, Melanie Rüger, Federico Fratelli, et al.
Psychiatry Research|January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trialsStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Neuropsychiatric Disease and Treatment|June 11, 2021
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled TrialsAzmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
British Journal of Clinical Pharmacology|May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Psychiatry Research|November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trialStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Clinical Therapeutics|March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled TrialAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Pageof 3